Th1 cytokines accentuate but Th2 cytokines attenuate ceramide production in the stratum corneum of human epidermal equivalents: An implication for the disrupted barrier mechanism in atopic dermatitis

Journal of Dermatological Science

Volumn 68, Issue 1, 2012, Pages 25-35

  Sawada, Eri ^a   Yoshida, Naoki ^a,b   Sugiura, Ayumi ^a   Imokawa, Genji ^a,c  

^a TOKYO UNIVERSITY OF TECHNOLOGY   (Japan)

^b Ikeda Mohando Co Ltd   (Japan)

^c CHUBU UNIVERSITY   (Japan)

Author keywords

Atopic dermatitis; Ceramide; Human epidermal equivalent; Stratum corneum; Th1 cytokine; Th2 cytokine

Indexed keywords

BETA GLUCOCEREBROSIDASE; CERAMIDE; CYTOKINE; GAMMA INTERFERON; GLUCOSYLCERAMIDASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; INTERLEUKIN 6; SERINE PALMITOYLTRANSFERASE; SERINE PALMITOYLTRANSFERASE 2; SPHINGOLIPID; SPHINGOMYELIN PHOSPHODIESTERASE; TH1 CYTOKINE; TH2 CYTOKINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; ATOPIC DERMATITIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; EPIDERMIS; GENE EXPRESSION REGULATION; LIPOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; STRATUM CORNEUM;

CELLS, CULTURED; CERAMIDES; CYTOKINES; DERMATITIS, ATOPIC; DOWN-REGULATION; EPIDERMIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOSYLCERAMIDASE; HUMANS; KERATINOCYTES; RECOMBINANT PROTEINS; SERINE C-PALMITOYLTRANSFERASE; SPHINGOMYELIN PHOSPHODIESTERASE; TH1 CELLS; TH2 CELLS; TIME FACTORS;

EID: 84865739457     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2012.07.004     Document Type: Article

References (38)

1. Imokawa G., Abe A., Jin K., Higaki Y., Kawashima M., Hidano A. Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin?. J Invest Dermatol 1991, 96:523-526.
2. Imokawa G., Kuno H., Kawai M. Stratum corneum lipids serve as a bound-water modulator. J Invest Dermatol 1991, 96:845-851.
3. Imokawa G. Skin moisturizers: development and clinical use ceramides. Dry skin and moisturizers 1999, 269-299. CRC Press. M. By, Loden (Eds.).
4. Imokawa G. Ceramides as natural moisturizing factors and their efficacy in dry skin. Skin moisturization 2002, 267-302. Marcel Dekker Inc. J.J. By Leyden, A.V. Rawlings (Eds.).
5. Imokawa G. Surfactant-induced depletion of ceramides and other intercellular lipids: implication for the mechanism leading to dehydration of the stratum corneum. Exog Dermatol 2004, 3:81-98.
6. Matsuki H., Kiyokane K., Matsuki T., Sato S., Imokawa G. Re-evaluation of the importance of barrier dysfunction in the non-lesional dry skin of atopic dermatitis through the use of two barrier creams. Exog Dermatol 2004, 3:293-302.
7. Takagi Y., Nakagawa H., Higuchi K., Imokawa G. Characterization of surfactant-induced skin damage through barrier recovery induced by pseudoacylceramide. Dermatology 2005, 211:128-134.
8. Jin K., Higaki Y., Takagi Y., Higuchi K., Yada Y., Kawashima M., et al. Analysis of beta-glucocerebrosidase and ceramidase activity in atopic and aged dry skin. Acta Derm Venereol 1994, 74:337-340.
9. Higuchi K., Hara J., Okamoto R., Kawashima M., Imokawa G. The skin of atopic dermatitis patients contains a novel enzyme, glucosylceramide sphingomyelin deacylase, which cleaves the N-acyl linkage of sphingomyelin and glucosylceramide. Biochem J 2000, 350:747-756.
10. Ishibashi M., Arikawa J., Okamoto R., Kawashima M., Takagi Y., Oguchi K., et al. The abnormal expression of the novel epidermal enzyme, glucosylceramide deacylase and the accumulation of its enzymatic reaction product, glucosylsphingosine in the skin of patients with atopic dermatitis. Lab Invest 2003, 88:397-408.
11. Kusuda S., Cui C.Y., Takahashi M., Tezuka T. Localization of sphingomyelinase in lesional skin of atopic dermatitis patients. J Invest Dermatol 1998, 111:733-738.
12. Jensen J.M., Fölster-Holst R., Baranowsky A., Schunck M., Winoto-Morbach S., Neumann C., et al. Impaired sphingomyelinase activity and epidermal differentiation in atopic dermatitis. J Invest Dermatol 2004, 122:1423-1431.
13. Murata Y., Ogata J., Higaki Y., Kawashima M., Yada Y., Higuchi K., et al. Abnormal expression of sphingomyelin acylase in atopic dermatitis: an etiologic factor for ceramide deficiency?. J Invest Dermatol 1996, 106:1242-1249.
14. Hara J., Higuchi K., Okamoto R., Kawashima M., Imokawa G. High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. J Invest Dermatol 2000, 115:406-413.
15. Okamoto R., Arikawa J., Ishibashi M., Kawashima M., Takagi Y., Imokawa G. Sphingosylphosphorylcholine levels are significantly increased in the stratum corneum of patients with atopic dermatitis: physiological and functional relevance of sphingomyelin deacylase to the ceramide deficiency. J Lipid Res 2003, 44:93-102.
16. Grewe M., Bruijnzeel-Koomen C.A.F.M., Schopf E., Thepen T., Langeveld-Wildschut A.G., Ruzicka T., et al. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 1998, 19:359-361.
17. Leung D.Y.M., Boguniewicz M., Howell M.D., Nomura I., Hamid Q.A. New insights into atopic dermatitis. J Clin Invest 2004, 113:651-657.
18. Leung D.Y., Jain N., Leo H.L. New concepts in the pathogenesis of atopic dermatitis. Curr Opin Immunol 2003, 15:634-638.
19. Yamazaki F., Aragane Y., Maeda A., Matsushita K., Ueno K., Yudate T., et al. Overactivation of IL-4-induced activator protein-1 in atopic dermatitis. J Dermatol Sci 2002, 28:227-233.
20. Kondo H., Ichikawa Y., Imokawa G. Percutaneous sensitization with allergens through barrier-disrupted skin elicits a Th2-dominant cytokine response. Eur J Immunol 1998, 28:769-779.
21. Hatano Y., Terashi H., Arakawa S., Katagiri K. Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factor-alpha and interferon-gamma in human epidermis. J Invest Dermatol 2005, 124:786-792.
22. Hatano Y., Katagiri K., Arakawa S., Fujiwara S. Interleukin-4 depresses levels of transcripts for acid-sphingomyelinase and glucocerebrosidase and the amount of ceramide in acetone wounded epidermis, as demonstrated in a living skin equivalent. J Dermatol Sci 2007, 47:45-47.
23. Yoshida N., Sawada E., Imokawa G. A reconstructed human epidermal keratinization culture model to characterize ceramide metabolism in the stratum corneum. Arch Dermatol Res 2012, 10.1007/s00403-012-1232-6.
24. Rheinwald J.G., Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 1975, 6:331-344.
25. Green H. Cyclic AMP in relation to proliferation of the epidermal cell: new view. Cell 1978, 15:801-811.
26. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37:911-917.
27. Takagi Y., Kriehuber E., Imokawa G., Elias P.M., Holleran W.M. Beta-glucocerebrosidase activity in mammalian stratum corneum. J Lipid Res 1999, 40:861-869.
28. Van Diggelent O.P., Voznyi Ya V., Keulemans J.L.M., Schoonderwoerd K., Ledvinova J., Mengel E., et al. A new fluorimetric enzyme assay for the diagnosis of Niemann-Pick A/B, with specificity of natural sphingomyelinase substrate. J Inheirt Metab Dis 2005, 28:733-741.
29. Takagi Y., Nakagawa H., Kondo H., Takema Y., Imokawa G. Decreased levels of covalently bound ceramide are associated with UVB-induced perturbation of the skin barrier. J Invest Dermatol 2004, 123:1102-1109.
30. Sonenberg N. e{open}IF4E, the mRNA cap-binding protein: from basic discovery to translational research. Biochem Cell Biol 2008, 86:178-183.
31. Schmuth M., Man M.Q., Weber F., Gao W., Feingold K.R., Fritsch P., et al. Permeability barrier disorder in Niemann-Pick disease: sphingomyelin-ceramide processing required for normal permeability barrier homeostasis. J Invest Dermatol 2000, 115:459-466.
32. Holleran W.M., Ginns E.I., Menon G.K., Grundmann J.U., Fartasch M., McKinney C.E., et al. Consequences of beta-glucocerebrosidase deficiency in epidermis. Ultrastructure and permeability barrier alterations in Gaucher disease. J Clin Invest 1994, 93:1756-1764.
33. Hanley K., Jiang Y., Holleran W.M., Elias P.M., Williams M.L., Feingold K.R. Glucosylceramide metabolism is regulated during normal and hormonally stimulated epidermal barrier development in the rat. J Lipid Res 1997, 38:576-584.
34. Grossman R.M., Krueger J., Yourish D., Granelli-Piperno A., Murphy D.P., May L.T., et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989, 86:6367-6371.
35. Neuner P., Urbanski A., Trautinger F., Moller A., Kirnbauer R., Kapp A., et al. A Increased IL-6 production by monocytes and keratinocytes in patients with psoriasis. J Invest Dermatol 1991, 97:27-33.
36. Motta S., Monti M., Sesana S., Mellesi L., Ghidoni R., Caputo R. Abnormality of water barrier function in psoriasis. Role of ceramide fractions. Arch Dermatol 1994, 130:452-456.
37. Motta S., Monti M., Sesana S., Caputo R., Carelli S., Ghidoni R. Ceramide composition of the psoriatic scale. Biochim Biophys Acta 1993, 1182:147-151.
38. Kurahashi R., Hatano Y., Katagiri K. IL-4 suppresses recovery of barrier function in vivo. J Invest Dermatol 2008, 128:1329-1331.